Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2005-03-08
2005-03-08
Li, Q. Janice (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C435S069500, C435S325000, C435S372000, C514S012200, C604S004010, C604S007000
Reexamination Certificate
active
06863885
ABSTRACT:
The present invention provides a method of engrafting donor mammalian hematopoietic pluripotent cells in a mammalian recipient using a decreased amount of radiation, comprising: (a) administering to the recipient at least one dosage of a hematopoietic growth factor; (b) subjecting the recipient to a low dosage of radiation; and (c) transplanting the donor hematopoietic pluripotent cells in the recipient, thereby engrafting the donor mammalian hematopoietic pluripotent cells in the mammalian recipient using a decreased amount of radiation. The invention also provides a method of engrafting donor mammalian hematopoietic pluripotent cells in a mammalian recipient using a decreased amount of radiomimetic compound, comprising: (a) administering to the recipient at least one dosage of a hematopoietic growth factor; (b) subjecting the recipient to a low dosage of radiomimetic compound; and (c) transplanting the donor hematopoietic pluripotent cells in the recipient, thereby engrafting the donor mammalian hematopoietic pluripotent cells in the mammalian recipient using a decreased amount of radiomimetic compound.
REFERENCES:
patent: 5004681 (1991-04-01), Boyse et al.
patent: 5078996 (1992-01-01), Conlon, III et al.
patent: 5106733 (1992-04-01), Baker et al.
patent: 5199942 (1993-04-01), Gillis
patent: 5843423 (1998-12-01), Lyman et al.
patent: 6103694 (2000-08-01), Mardiney, III et al.
patent: 065602 (1995-07-01), None
patent: WO21402 (1992-12-01), None
Cullis et al, Brit J Haematol 1992;80:33-9.*
Game et al, Wien Klin Wochenschr 2001;113:823-38.*
Down et al., “Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs,”Exp. Hem.21:913-921 (1993).
Tavassoli, M., “The role of conditioning regimens in homing of transplanted hemopoietic cell,”Bone Marrow Transplantation10:15-17(1992).
Mauch, P. et al., “Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy,”Int. J. Radiation Oncology Biol. Phys.,31(5): 1319-1339 (1995).
Uckun, F. et al., “in vivo radioprotective effects of recombinant human granulocyte colony-stimulating factor in lethally irradiated mice,”Blood, 75:638-645 (1990).
Weaver, C.H. et al., “Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies,”Bone Marrow Transplantation, 14:813-819 (1994).
Faucher, C. et al., “Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness,”Bone Marrow Transplanation, 14:895-901 (1994).
Vose, J.M. et al. “Clinical applications of hematopoietic growth factors,”J. Clin. Oncology,13(4):1023-1035 (1995).
Wilson et al., “Interleukin-I administration before high-dose ifosamide (I), CBDCA (C), and etoposide (E) (ICE) with autoogous bone marrow shortens neutrophil recovery: a phase I/II study,”Proc. Am. Soc. Clin. Oncol.,12:937a (1993).
Talmadge, J.E., “The combination of stem cell transplantation and immunotherapy: future potential,” In vivo, 8:675-690 (1994).
Juttner, C.A. et al., “Blood cell transplantation: report from an international consensus meeting,”Bone Marrow Transplantation,14:689-693 (1994).
George, M. J., “The present and future of hematopoietic cytokines in clinical practice,”Polyfunctionality of Hematopoietic Regulators: The Metcalf Forum. STEM CELLS,12 (supp I): 249-255 (1994).
Nemunaitis, J., “Biological activities of hematopoletic growth factors that lead to future clinical application,”Cancer Investigation,12(5): 516-529(1994).
Cobbold et al. “Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance”,Nature, 323:164-166, 1992.
Colson, et al., “A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor and hematopoietic histocompatability barriers”J. Immunol., 155:4179-4188, 1995.
Manual of Oncology Therapeutics, See-Lasley (Ed.), The C.V. Mosby Co., St. Louis, pp. 17, 88 and 104, 1981.
Moore et al. “Synergy of interleukin 1 and granulocyte colony-stimulating factor: In vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice”Proc. Natl. Acad. Sci.-USA, 84:7134-7138, 1987.
Rosenzweig et al. “Efficient and durable gene marking of hematopoietic progenitor cells in non-human primates after non-ablative conditioning”Blood, 94(7):2271-86, 1999.
Sheridan et al. “Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy”The Lancet, 339:640-644, 1992.
Storb et al DLA-Identifical bone marrow grafts after low-dose total body irradiation: The effect of canine recombinant hematopoietic growth factorsBlood84(10):3558-3566, 1994.
Malech Harry L.
Mardiney, III Michael
Li Q. Janice
Needle & Rosenberg P.C.
The United States of America as represented by the Department of
LandOfFree
Method of decreasing radiation or radio-mimetic chemotherapy... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of decreasing radiation or radio-mimetic chemotherapy..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of decreasing radiation or radio-mimetic chemotherapy... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3456317